Champions Oncology (NASDAQ:CSBR) Shares Pass Below Two Hundred Day Moving Average – Time to Sell?

Champions Oncology, Inc. (NASDAQ:CSBR) passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $5.85 and traded as low as $5.00. Champions Oncology shares last traded at $5.00, with a volume of 2,050 shares.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered shares of Champions Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 30th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Champions Oncology presently has a consensus rating of “Sell”.

Champions Oncology Price Performance

The business’s 50 day moving average is $5.56 and its two-hundred day moving average is $5.85. The firm has a market capitalization of $73.50 million, a PE ratio of -66.00 and a beta of 0.40.

Champions Oncology (NASDAQ:CSBR) last released its quarterly earnings results on Monday, July 27th. The biotechnology company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.06. The business had revenue of $13.84 million during the quarter, compared to analysts’ expectations of $12.89 million. Champions Oncology had a negative net margin of 1.87% and a negative return on equity of 27.48%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd bought a new stake in Champions Oncology during the second quarter worth about $103,000. Essex Investment Management Co. LLC bought a new position in shares of Champions Oncology during the 4th quarter valued at about $126,000. Bank of New York Mellon Corp bought a new position in shares of Champions Oncology during the 2nd quarter valued at about $133,000. Jane Street Group LLC purchased a new position in shares of Champions Oncology during the 1st quarter valued at about $200,000. Finally, Goldman Sachs Group Inc. purchased a new position in shares of Champions Oncology during the 1st quarter valued at about $201,000. 41.30% of the stock is currently owned by hedge funds and other institutional investors.

Champions Oncology Company Profile

Champions Oncology, Inc engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients.